Our RESETTM clinical trials with rese-cel (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 02/10/22 | SC 13G/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
|
7 | |
| 02/02/22 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 01/19/22 | 4 | Statement of changes in beneficial ownership of securities |
|
3 | |
| 01/19/22 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 01/19/22 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 01/19/22 | 4 | Statement of changes in beneficial ownership of securities |
|
3 | |
| 01/19/22 | 4 | Statement of changes in beneficial ownership of securities |
|
3 | |
| 01/19/22 | 4 | Statement of changes in beneficial ownership of securities |
|
3 | |
| 01/13/22 | 3 | Initial statement of beneficial ownership of securities |
|
3 | |
| 01/10/22 | 8-K | Current report filing |
|
   |
31 |
